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a b s t r a c t
Postmenopausal women with chronic hepatitis C exhibited a poor response to interferon (IFN) therapy
compared to premenopausal women. Osteoporosis is the typical complication that occurs in post-
menopausal women. Recently, it was reported that an osteoporotic reagent, vitamin D3, exhibited
anti-hepatitis C virus (HCV) activity. Therefore, we investigated whether or not another osteoporotic
reagent, raloxifene, would exhibit anti-HCV activity in cell culture systems. Here, we demonstrated that
raloxifene inhibited HCV RNA replication in genotype 1b and infection in genotype 2a. Raloxifene en-
hanced the anti-HCV activity of IFN-α. These results suggest a link between the molecular biology of
osteoporosis and the HCV life cycle.
c© 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Hepatitis C virus (HCV) belongs to the Flaviviridae family and con-
tains a positive single-stranded RNA genome of 9.6 kb. The HCV
genome encodes a single polyprotein precursor of approximately
3000 amino acid residues, which is cleaved by the host and viral
proteases into at least 10 proteins in the following order: Core, en-
velope 1 (E1), E2, p7, nonstructural 2 (NS2), NS3, NS4A, NS4B, NS5A,
and NS5B [1–3].
The virological study and screening of antiviral reagents for HCV
was difﬁcult until the replicon system was developed [4–7]. In 2005,
an infectious HCV production system was developed using genotype
2a HCV JFH-1 and hepatoma-derived HuH-7 cells, and the HCV life
cycle was reproduced in a cell culture system [8]. We previously
developed genome-length HCV reporter assay systems using HuH-
7-derived OR6 cells [4]. In OR6 cells, the genotype 1b HCV-O with
renilla luciferase (RL) replicates robustly. We also developed an HCV
JFH-1 reporter infection assay system [9].
HCV infection frequently causes chronic hepatitis (CH) and leads to
serious liver cirrhosis and hepatocellular carcinoma. Therefore, HCV
infection is a major health problem worldwide. The elimination of
HCV by antiviral reagents seems to be the most efﬁcient therapy for
preventing the fatal state of the disease. Pegylated-interferon (PEG-
IFN) with ribavirin (RBV) is the current standard therapy for CH–C,1 These authors contributed equally to this work.
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50%. Recently, a protease inhibitor, telaprevir, improved the SVR rate
by up to 60–70% in combinationwith PEG-IFN/RBV [10]. The response
to PEG-IFN/RBV therapy depends on host factors as well as viral fac-
tors. Among the host factors, age and gender are known to be associ-
ated with the outcome of IFN/RBV therapy [11,12]. Postmenopausal
women with CH–C exhibited a poor response to IFN therapy com-
pared to premenopausal women [11]. The decrease in estrogen may
affect the response to IFN therapy. Dyslipidemia and osteoporosis are
the typical complications in postmenopausal women. We and other
groups reported that statins, which are dyslipidemia reagents, inhib-
ited HCV proliferation in vitro and in vivo [13–17]. Recently it was
reported that vitamin D3, an osteoporotic reagent, exhibited anti-
HCV activity in vitro and in vivo [18–21]. It was also reported that
17β-estradiol inhibited the production of infectious HCV [22]. Taken
together, these reports suggest an association between hepatitis C
and complications due to the decrease of estrogen.
Raloxifene and tamoxifen are synthetic selective estrogen receptor
modulators (SERMs) and are used for breast cancer and osteoporosis,
respectively, in clinical settings. The responses of SERMs are medi-
ated by estrogen receptors (ERs), either ERα or ERβ. SERMs exhibit
agonistic actions in some tissues but antagonistic actions in others.
Both raloxifene and tamoxifen are antagonists in breast and agonists
in bone. However, only tamoxifen, and not raloxifene, exhibited ago-
nistic activity in the uterus. It was reported that tamoxifen inhibited
HCV RNA replication [23]. However, tamoxifen’s agonist action leads
to uterine cancer. Raloxifene belongs to an antiosteoporotic reagent
and offers the advantage of safety without uterine cancer. Therefore,
we decided to investigate whether or not raloxifene would exhibit
anti-HCV activity in our developed cell culture systems..V. Open access under CC BY-NC-ND license.
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2.1. Reagents and antibodies
Raloxifene was purchased from LKT Laboratories, Inc. (St. Paul,
MN). IFN-α and tamoxifen were purchased from Sigma–Aldrich (St.
Louis, MO). Pitavastatin (PTV) was purchased from Kowa Company
(Nagoya, Japan). The antibodies used in this study were those spe-
ciﬁc to HCV Core (CP11, Institute of Immunology, Tokyo, Japan), NS3
(Novocastra Laboratories, Newcastle, UK), and β-actin (Sigma).
2.2. Cell culture and HCV RNAs
HuH-7 cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
(Gibco-BRL, Invitrogen Life Technology, Carlsbad, CA) supplemented
with 10% fetal bovine serum, penicillin, and streptomycin. HuH-7-
derived OR6 and sOR cells were genome-length and subgenome HCV
(O strain of genotype 1b) RNA harboring cells, respectively and cul-
tured in the above medium supplemented with G418 (0.3 mg/ml;
Geneticin, Invitrogen) [4]. HCVs replicating in OR6 and sOR cells
contain RL and neomycin phosphotransferase (NPT) genes after 5′-
untranslated region (UTR). HuH-7-derived RSc cells are cured cells, in
which HCV RNAwas eliminated by IFN-α; they are used for HCV JFH-
1 infection [9]. RSc cells are also used for subgenomic JFH-1 RNA (JRN/
35B) replication. JRN/35B contains RL and NPT genes after 5′-UTR.
2.3. RL assay
For the RL assay, 1.5×104 OR6 were plated onto 24-well plates
in triplicate and cultured for 24 h. The cells were treated with each
reagent for 72 h. Then the cells were harvested with Renilla lysis
reagent (Promega, Madison, WI) and subjected to RL assay according
to the manufacturer’s protocol.
2.4. WST-1 cell proliferation assay
The cells (2×103 cells) were plated onto a 96-well plate in tripli-
cate at 24 h before treatment with each reagent. At 72 h after treat-
ment, the cells were subjected to a WST-1 cell proliferation assay
(Takara Bio, Otsu, Japan) according to the manufacturer’s protocol.
2.5. Western blot analysis
For Western blot analysis, 4×104 cells were plated onto 6-well
plates, cultured for 24 h, and then treated with reagent(s) for 72 h
and 120 h. Preparation of the cell lysates, sodium dodecyl sulfate–
polyacrylamide gel electrophoresis, and immunoblotting were then
performed as previously described [24]. Immunocomplexes on the
membranes were detected by enhanced chemiluminescence assay
(Renaissance; Perkin Elmer Life Science, Wellesley, MA).
2.6. HCV infection
RSc cells (1.5×104 cells) were plated onto a 24-well plate 24 h
before infection. To evaluate the effect of the treatment prior to in-
fection, the cells were ﬁrst treated with raloxifene for 24 h, then
inoculated with reporter JFH-1 (JR/C5B/BX-2) supernatant at a mul-
tiplicity of infection (MOI) of 0.2, cultured for 48 h, and subjected to
RL assay as described previously [9]. The JR/C5B/BX-2 contains the
RL gene in the ﬁrst cistron following the encephalomyocarditis virus-
internal ribosomal entry site (EMCV-IRES) gene and the open reading
frame (ORF) of JFH-1 in the second cistron. To evaluate the effect of
the treatment after infection, the cells were inoculated with reporter
JFH-1 supernatant at MOI of 0.2, cultured for 72 h, and subjected to
RL assay.3. Results
3.1. Raloxifene inhibited HCV RNA replication
The HCV RNA that replicated in HuH-7-derived OR6 cells was a
genome-length HCV with RL, NPT, and EMCV-IRES in the ﬁrst cistron
and the ORF of HCV (O strain of genotype 1b) in the second cistron [4].
OR6 cells could not produce infectious HCV. Therefore, we can moni-
tor the replication step in theHCV life cycle usingOR6 cells. Raloxifene
inhibited HCV RNA replication in a dose-dependent manner, and its
50% effective concentration (EC50) was 1μM (Fig. 1A). Raloxifene did
not exhibit cytotoxicity to OR6 cells until 2.5μM (Fig. 1B). Raloxifene
also inhibited intracellular Core and NS3 production in a dose- and
time-dependent manner (Fig. 1C). The intensities of Core and NS3 in
OR6 cells treated with 2.5 μM of raloxifene decreased to almost the
level of cells treated with 10 IU/ml of IFN-α at 120 h after treatment.
We also examined anti-HCV activity of raloxifene using subgenomic
HCV replicon harboring sOR cells. Raloxifene exhibitedweak anti HCV
activity to sOR cells as compared with OR6 cells (Supplementary Figs.
1A and 1B). These results suggest that raloxifene exhibits anti-HCV
activity and decreased the expression levels of HCV proteins more
slowly compared to IFN-α.
3.2. Raloxifene enhanced anti-HCV activity of IFN-α
We investigated the anti-HCVactivity of raloxifene in combination
with a representative anti-HCV reagent, IFN-α. HCV RNA replication
decreased in a dose-dependent manner after co-treatment with IFN-
α and raloxifene (Fig. 2A). The results were almost similar to the ex-
pected effect of raloxifene in combinationwith IFN-α calculated from
the anti-HCV activity of each reagent (Fig. 2B). These results indicate
that the anti-HCV activity of raloxifene and IFN-α exhibited additive
effect. We also examined the anti-HCV activity of previously reported
SERM, tamoxifen. Tamoxifen also exhibited additive anti-HCVactivity
on HCV RNA replication in combination with IFN-α (Supplementary
Figs. 2A–C). These results indicate that raloxifene aswell as tamoxifen
enhanced the anti-HCV activity of IFN-α. As both raloxifene and IFN-
α are clinically used reagents, raloxifene seemed to be a candidate
reagent as an add-on treatment to IFN-α in patients with CH–C.
3.3. Raloxifene antagonized anti-HCV activity of statin
We previously reported that statins exhibited anti-HCV activity
using the OR6 assay system [14]. Statin is the ﬁrst-choice reagent for
dyslipidemia. As dyslipidemia and osteoporosis are major complica-
tions in postmenopausal women, we invested the effect of raloxifene
on the anti-HCV activity of PTV. Raloxifene did not enhance the anti-
HCV activity of PTV (Fig. 3A). Fig. 3B exhibits the expected anti-HCV
activity of co-treatment with raloxifene and PTV calculated from the
anti-HCV effect of either raloxifen or PTV alone. Raloxifene exhibited
an antagonistic effect on PTV’s anti-HCV activity. Raloxifene’s antag-
onistic effect on PTV increased dose-dependently. The co-treatment
with raloxifene (2.5 μM) and PTV (0.25, 0.5, and 1 μM) resulted in
lower anti-HCV activity than did treatment with raloxifene alone (2.5
μM). These results suggest that we should be careful in the admin-
istration of statins with raloxifene to postmenopausal woman with
CH–C.
3.4. Raloxifene inhibited infection of genotype 2a HCV
To further investigate the anti-HCV activity of raloxifene, we ex-
aminedwhether or not raloxifene could inhibit HCV infection. For this
purpose, we used our recently developed JFH-1 reporter infection as-
say system [9]. HuH-7-derived RSc’s are highly HCV-permissive cell
lines. Raloxifenewas pretreated at 24hbeforeHCV infection. The cells
were inoculated with HCV JFH-1 virion with RL (JR/C5B/BX-2), and
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Fig. 1. Raloxifene inhibited HCV RNA replication. (A) Anti-HCV activity of raloxifene
in OR6 cells. OR6 cells were treated with raloxifene (0, 0.625, 1.25, and 2.5 μM) for 72
h. Relative RL activity (relative light unit: RLU) for HCV RNA replication is expressed as
a percentage of control. Each bar represents the average with standard deviations of
triplicate data points. (B) Effect of raloxifene on OR6 cell viability. Cell viability at 72 h
after raloxifene treatment (0.15, 0.31, 0.625, 1.25, 2.5, 5, and 10 μM) was determined
using WST-1 cell proliferation assay and is expressed as a percentage of control. (C)
Raloxifene inhibited HCV proteins. OR6 cells were treated with IFN-α (10 IU/ml) or
raloxifene (0, 0.625, 1.25, and 2.5 μM). After 72 or 120 h treatment, the production of
Core and that of NS3 were analyzed by immunoblotting using anti-Core and anti-NS3
antibodies, respectively. OR6c cells were cured cells in which HCV RNAwas eliminated
using IFN-α, and were used as a negative control.β-actin was used as a control for the
amount of protein loaded per lane.
the infection was monitored with RL activity at 48 h after infection.
As shown in Fig. 4A, raloxifene inhibited HCV infection in RSc cells in
a dose-dependent manner. Next we examined the effect of raloxifene
after HCV infection. RSc cells were inoculated with HCV JFH-1 virion
with RL. After HCV infection, the cells were treatedwith raloxifene for
72 h and raloxifene’s inhibitory effect on post-infection was assessed
using the RL assay. Raloxifene inhibited HCV proliferation in a dose-
dependent manner when it was added to the cells after infection in
RSc cells, although inhibitory effect of raloxifene on JFH-1 HCV RNA
replication seemed to be weak compared to the genotype 1b HCV-
O RNA replication (Fig. 4B). Raloxifene did not exhibit cytotoxicity
to RSc cells until 2.5 μM (Fig. 4C). We found that raloxifene could
not inhibit subgenomic JFH-1 HCV (JRN/35B) RNA replication (Fig.
4D). We further examined the inhibitory action of raloxifene around
infection step. RSc cells were treated for short time with raloxifene
around infection step: for 1, 4, and 4 h before, during, and after in-
oculation, respectively (Fig. 4E). Raloxifene inhibited JFH-1 infection,
when it was treated during inoculation but not just before or after in-
oculation. In case of genotype 2a JFH-1, raloxifene’s anti-HCV activity
is mainly due to the inhibition of infection. These results indicate that
Fig. 2. Raloxifene enhanced the anti-HCV activity of IFN-α. (A) Anti-HCV activity of
raloxifene in combination with IFN-α. OR6 cells were co-treated with raloxifene (0,
0.625, 1.25, and 2.5 μM) and IFN-α (0, 0.63, 1.25, 2.5, 5, 10 IU/ml). Relative RL activity
is shown as a percentage of control. Each bar represents the average with standard
deviations of triplicate data points. (B) Expected anti-HCV activitywas calculated based
on the results when the cells were treated with only raloxifene or IFN-α.
Fig. 3. Statin antagonized the anti-HCV activity of raloxifene. (A) OR6 cells were co-
treated with raloxifene (0, 0.625, 1.25, and 2.5 μM) and PTV (0, 0.25, 0.5, and 1 μM).
Relative RL activity was shown as a percentage of control. Each bar represents the av-
erage with standard deviations of triplicate data points. (B) Expected anti-HCV activity
was calculated based on the results when the cells were treated with only raloxifene
or PTV.
raloxifene inhibits JFH-1 infection but not its RNA replication.
4. Discussion
In this study, we demonstrated that raloxifene, an osteoporotic
reagent, inhibited the replication of genotypes 1b HCV RNA replica-
tion and inhibited genotype 2a HCV JFH-1 infection. Raloxifene ad-
ditively enhanced the anti-HCV activity of IFN-α. On the other hand,
raloxifene exhibited an antagonistic effect on statins.
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Fig. 4. Raloxifene inhibited genotype 2a HCV infection. (A) Raloxifene inhibited HCV
JFH-1 infection. RSc cells were treated with raloxifene (0, 0.31, 0.625, 1.25, 2.5, 5, and
10 μM) 24 h before infection. HCV JFH-1 reporter virion was used as an inoculum
after removal of raloxifene. The cells were then infected with reporter JFH-1 virion
and cultured for 48 h. The inhibition of HCV infection was assessed by relative RL
activity and expressed as a percentage of control. (B) Raloxifene inhibited HCV JFH-1
proliferation after infection. RSc cells were inoculated with HCV JFH-1 reporter virion
and cultured for 24 h. Then the cells were treated with raloxifene (0, 0.31, 0.625, 1.25,
2.5, 5, and 10 μM) for 48 h. The inhibitory effect on HCV proliferation after infection
was assessed by relative RL activity and expressed as a percentage of control. Each bar
represents the average with standard deviations of triplicate data points. (C) Effect of
raloxifene on RSc cells viability. Cell viability at 72 h after raloxifene treatment (0.15,
0.31, 0.625, 1.25, 2.5, 5, and 10 μM) was determined using WST-1 cell proliferation
assay and is expressed as a percentage of control. (D) Subgenomic JFH-1 RNA (JRN/35B)
replicating RSc cells were treated with raloxifene (0, 0.625, 1.25, and 2.5 μM) for 72
h. Relative RL activity for HCV RNA replication is expressed as a percentage of control.
Each bar represents the average with standard deviations of triplicate data points. (E)
Raloxifene (0, 0.625, 1.25, and 2.5 μM) was treated for 1, 4, and 4 h before, during,
and after JFH-1 inoculation to RSc cells at MOI of 0.2, respectively. The cells were then
cultured for 72 h. The inhibition of HCV infection was assessed by relative RL activity
and expressed as a percentage of control.
PEG-IFN/RBV therapy led to a 40–50% SVR rate among patients
with CH–C. Telaprevir with PEG-IFN/RBV increases the effect of PEG-
IFN/RBV therapyby10–20%.However, themajor complication of ane-
mia in PEG-IFN/RBV therapy increased when telaprevir was added.
Considering that PEG-IFN/RBV-based therapy is less effective onpost-
menopausal women, an alternative therapy with minimal side ef-
fects is needed. Add-on therapy for postmenopausal women may be
a candidate for improving the SVR in these patients. We focused on
the reagents, which compensate for the lack of estrogen function.
Dyslipidemia and osteoporosis are the major complications in post-
menopausal women, and these complications are attributable to the
decrease in estrogen. Statins are clinically used reagents for dyslipi-
demia; they inhibit HCV RNA replication in vivo as well as in vitro
[13–17]. Therefore, we investigated whether or not raloxifene ex-
hibits anti-HCV activity using genotype 1b HCV RNA replication and
genotype 2a infection systems. In the HCV life cycle, raloxifene inhib-
ited genotype 2a HCV infection and genotypes 1b HCV RNA replica-
tion. Raloxifene may be a potential reagent with different anti-HCV
mechanisms in the HCV life cycle. Further study is needed to clarify
these underlying mechanisms.
Recently it was reported that vitamin D3, an osteoporotic reagent,
inhibited HCV production in cell culture systems [20,21]. Further-
more, it was reported that vitamin D3 was associated with the
effect of therapy for patients with CH–C [18,19]. Statins inhibited
HCV RNA replication by suppressing geranylgeranyl pyrophosphate
(GGPP) production [14]. Another osteoporotic reagent, bisphospho-
nate, may possess anti-HCV activity, because it also inhibited the
biosynthesis of GGPP in the mevalonate pathway by inhibiting farne-
syl pyrophosphate synthetase. Taken together, these ﬁndings indicate
it is likely that the HCV life cycle is associated with osteoporosis.
Raloxifene and tamoxifen are SERMs for osteoporosis and breast
cancer, respectively. Tamoxifen is used for estrogen receptor-positive
breast cancer, and it inhibits HCV RNA replication in cell culture [23].
Tamoxifen’s anti-HCV activity is associated with ERα. In our study,
raloxifene inhibited HCV infection as well as replication. To clarify
the multi-potential effects of raloxifene, further study is needed. The
incidence of side effects includinguterine cancer is lower in raloxifene
therapy than in tamoxifen therapy [25]. This is another advantage of
raloxifene in clinical use for patients with CH–C.
As for the precise role of ERα or ERβ on the HCV life cycle, we
could not reach a clear conclusion because microarray analysis re-
vealed an absence of expression for both ERα and ERβ in OR6 cells
(data not shown). Hayashida et al. [22] reported that the most potent
physiological estrogen, 17-β-estradiol, inhibited infectious HCV pro-
duction using HuH-7.5 cells, and that ERα-selective agonist inhibited
infectious HCV production whereas ERβ-selective agonist did not.
Watashi et al. [23] reported that RNA interference-mediated knock-
down of ERα reduced HCV RNA replication. In our study, the anti-
HCV activity of raloxifene in infection and replication did not seem
attributable to ERα or ERβ. It is not clear why our HuH-7-derived
OR6 cells did not express ERα or ERβ. HuH-7 cells were developed
in 1982 at Okayama University and distributed worldwide [26]. Re-
cently, Bensadoun et al. [27] reported that the genetic background of
the IL28B genotype of HuH-7 cells differed among different laborato-
ries. Thismay be a consequence of the polyploidal nature of hepatoma
cells. A similarmechanismmight cause the different expression levels
of ERα and ERβ. Another ER, GPR30 [28], was expressed in OR6 cells
(data not shown; from microarray analysis). GPR30 may be the re-
sponsible host factor for anti-HCV activity in OR6 cells. Further study
is needed to clarify this issue.
In conclusion, we found that raloxifene inhibited HCV RNA repli-
cation in genotype 1b and infection in genotype 2a. Raloxifene ad-
ditively enhanced the anti-HCV activity of IFN-α. The antagonistic
effects of statins and raloxifene will yield information on the clinical
use of these reagents. Our results, as well as the reports of vitamin
D3’s anti-HCV activity, will open new ﬁelds of treatment for both
osteoporosis and HCV infection.
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